1. Optimal cytoreduction followed by chemoradiation in stage IVB uterine serous carcinoma
- Author
-
Jennifer McEachron, Nancy Zhou, Victoria Hastings, Michelle Bennett, Constantine Gorelick, Margaux J. Kanis, and Yi-Chun Lee
- Subjects
Uterine serous carcinoma ,Chemotherapy ,Radiation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Objectives: The prognosis of patients presenting with stage IVB uterine serous carcinoma (USC) remains extremely poor, with a reported 5-year survival of 1 cm. Progression free survival (PFS) and overall survival (OS) analysis was performed using Kaplan-Meier estimates. Multivariate analysis (MVA) was performed using Cox proportional hazards model. Results: Final analysis included 68 patients. There was no difference in the frequency of treatment delays between regimens (p = 0.832). 96% of patients received platinum-based chemotherapy. There was no difference in the age (p = 0.227), race (p = 0.936), type of radiotherapy (p = 0.852) or chemotherapy regimen received (p = 0.996) between R1 and R2 cohorts. The median PFS for all patients was 8 months and the median OS was 13 months. Cytoreduction to R1 was associated with a median PFS of 9 months, compared to R2 with a median PFS of 4 months (p
- Published
- 2022
- Full Text
- View/download PDF